Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 9/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700053 | 0.79 | EGFR (0.46) | NAMPTEGFRALDH1A1SMN1; SMN2ERBB2 | |
| SCHEMBL18318465 | 0.68 | NAMPT (0.49) | NAMPTUSP2POLBMAPK1ALDH1A1 | |
| SCHEMBL18319017 | 0.68 | NAMPT (0.49) | NAMPTUSP2POLBMAPK1ALDH1A1 | |
| SCHEMBL1386571 | 0.68 | EGFR (0.74) | EGFRERBB2 | |
| SCHEMBL4080241 | 0.68 | EGFR (0.74) | EGFRERBB2 | |
| SCHEMBL4090572 | 0.68 | EGFR (0.74) | EGFRERBB2 | |
| SCHEMBL18318322 | 0.66 | NAMPT (0.50) | NAMPTPOLBMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18318324 | 0.66 | NAMPT (0.50) | NAMPTPOLBMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18318726 | 0.66 | NAMPT (0.50) | NAMPTALDH1A1KDM4E | |
| SCHEMBL18318724 | 0.66 | NAMPT (0.50) | NAMPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | claimed |